{"id":56793,"date":"2012-11-09T05:51:56","date_gmt":"2012-11-09T05:51:56","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/general-authorization-to-export-medicine-to-iran-has-pitfalls.php"},"modified":"2012-11-09T05:51:56","modified_gmt":"2012-11-09T05:51:56","slug":"general-authorization-to-export-medicine-to-iran-has-pitfalls","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/general-authorization-to-export-medicine-to-iran-has-pitfalls.php","title":{"rendered":"General Authorization to Export Medicine to Iran Has Pitfalls"},"content":{"rendered":"<p><p>    WASHINGTON, Nov. 8, 2012 \/PRNewswire-iReach\/ -- On October 22,    2012 the United States Department of the Treasury's Office of    Foreign Assets Control (\"OFAC\") completely revised and reissued    the foundation of the U.S. economic sanctions program    prohibiting trade with Iran: the Iranian Transactions    Regulations (ITR). One of the key changes that occurred as    result of the revisions to the ITR, now re-named the Iranian    Transactions and Sanctions Regulations (ITSR), is the issuance    of a general license which authorizes the exportation and    reexportation of medicine and basic medical supplies to Iran.    Prior to this action, U.S. exporters of these products were    required to secure a specific license from the Treasury    Department's Office of Foreign Assets Control (OFAC) in order    to trade with Iran. Notably, the new regulations also contain    general authorization for a variety of payment and financing    methods for these exports. However, while the ITSR now opens up    a number of opportunities for U.S. medical companies,    restrictions on certain products remain, which require the    procurement of a specific license to export.   <\/p>\n<p>    For example, some of the more notable medicines which fall    under the exclusions to this authorization include: Xanax,    Vicodin, OxyContin, Percocet, Wellbuterin, Dramamine,    Wellbuterin, Advil PM, Benadryl, and Oral Steroid Painkillers.    These medicines all fall under the several categories of    medicine which are not covered by the general license. Those    categories include Non-NSAID analgesics, anticholinergics,    opiods, benzodiazepines, legal narcotics, and bioactive    peptides. In order to export any of these items, U.S. companies    must first obtain a specific license from OFAC.  <\/p>\n<p>    OFAC also provides a list of basic medical supplies which fall    under the general license. This list covers only the most    rudimentary devices, such as bandages, tongue depressors,    scalpels and other items which previously did not require an    Official Commodity Classification of EAR99 from the Department    of Commerce's Bureau of Industry and Security (BIS). For    exporters of medical devices not contained in the list of basic    medical supplies, a specific license and a BIS EAR99    classification are still required before any trade with    Iran may be conducted.  <\/p>\n<p>    Finally, while these new authorizations may seem like a boon    for U.S. exporters and a god send for those in Iran who need    such products, there is still great difficulty in finding U.S.    banks to process payments for these exports. Since they can no    longer rely on a specific license issued by OFAC, U.S. banks    have to trust that the transactions for which they are    requested to process payments are authorized under these new    regulations. As such, the risk of processing a payment which    may be in violation of the sanctions could be greater than    ever. Therefore, compliance measures should be bolstered both    by the exporters and the banking community to ensure all facets    of the new authorizations are adhered to.  <\/p>\n<p>    The ITSR is an exceptionally complex set of regulations and it    is suggested that exporters seek out an attorney specializing    in export and OFAC-related matters before going through with    any transactions related to Iran.  <\/p>\n<p>    Ferrari & Associates, P.C. is a    boutique law firm in Washington, DC specializing in OFAC    matters. If you have any questions regarding this press release    please contact them at 202-280-6370 or     <a href=\"mailto:info@ferrariassociatespc.com\">info@ferrariassociatespc.com<\/a>.  <\/p>\n<p>    Media Contact: Erich Ferrari, Ferrari & Associates,    P.C., 202-280-6370, <a href=\"mailto:ferrari@ferrariassociatespc.com\">ferrari@ferrariassociatespc.com<\/a>  <\/p>\n<p>    News distributed by PR Newswire iReach: <a href=\"https:\/\/ireach.prnewswire.com\" rel=\"nofollow\">https:\/\/ireach.prnewswire.com<\/a>  <\/p>\n<\/p>\n<p>Read the original: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/general-authorization-export-medicine-iran-030100946.html;_ylt=A2KJjancmZxQlVkAQ3L_wgt.\" title=\"General Authorization to Export Medicine to Iran Has Pitfalls\">General Authorization to Export Medicine to Iran Has Pitfalls<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> WASHINGTON, Nov. 8, 2012 \/PRNewswire-iReach\/ -- On October 22, 2012 the United States Department of the Treasury's Office of Foreign Assets Control (\"OFAC\") completely revised and reissued the foundation of the U.S. economic sanctions program prohibiting trade with Iran: the Iranian Transactions Regulations (ITR) <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/general-authorization-to-export-medicine-to-iran-has-pitfalls.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[35],"tags":[],"class_list":["post-56793","post","type-post","status-publish","format-standard","hentry","category-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/56793"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=56793"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/56793\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=56793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=56793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=56793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}